These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9137790)

  • 1. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.
    Reni M; Ferreri AJ; Garancini MP; Villa E
    Ann Oncol; 1997 Mar; 8(3):227-34. PubMed ID: 9137790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
    Ferreri AJ; Reni M; Villa E
    Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.
    Reni M; Ferreri AJ; Guha-Thakurta N; Blay JY; Dell'Oro S; Biron P; Hochberg FH
    Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):419-25. PubMed ID: 11567816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of treatment of primary CNS lymphoma.
    Ferreri AJ; Reni M; Pasini F; Calderoni A; Tirelli U; Pivnik A; Aondio GM; Ferrarese F; Gomez H; Ponzoni M; Borisch B; Berger F; Chassagne C; Iuzzolino P; Carbone A; Weis J; Pedrinis E; Motta T; Jouvet A; Barbui T; Cavalli F; Blay JY
    Neurology; 2002 May; 58(10):1513-20. PubMed ID: 12034789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system (CNS) lymphoma in immunocompetent patients.
    Plasswilm L; Herrlinger U; Korfel A; Weller M; Küker W; Kanz L; Thiel E; Bamberg M
    Ann Hematol; 2002 Aug; 81(8):415-23. PubMed ID: 12223997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
    Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
    Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
    Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
    Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary CNS lymphoma--an update].
    Soussain C; Houillier C; Choquet S; Hoang-Xuan K
    Bull Cancer; 2014 Mar; 101(3):314-24. PubMed ID: 24691194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
    Velasco R; Mercadal S; Vidal N; Alañá M; Barceló MI; Ibáñez-Juliá MJ; Bobillo S; Caldú Agud R; García Molina E; Martínez P; Cacabelos P; Muntañola A; García-Catalán G; Sancho JM; Camro I; Lado T; Erro ME; Gómez-Vicente L; Salar A; Caballero AC; Solé-Rodríguez M; Gállego Pérez-Larraya J; Huertas N; Estela J; Barón M; Barbero-Bordallo N; Encuentra M; Dlouhy I; Bruna J; Graus F;
    J Neurooncol; 2020 Jul; 148(3):545-554. PubMed ID: 32524392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
    Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M; Ferreri AJ
    Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of primary central nervous system lymphoma.
    Schultz CJ; Bovi J
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):666-78. PubMed ID: 20159361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
    Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
    Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
    Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
    Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.